Cardiac Biomarkers Are Associated with Increased Risks of Adverse Clinical Outcomes after Ischemic Stroke

Xinyue Chang,Shiliang Xia,Yang Liu,Xueyu Mao,Xuechun Wu,Min Chu,Huicong Niu,Lulu Sun,Yu He,Yi Liu,Daoxia Guo,Mengyao Shi,Yonghong Zhang,Zhengbao Zhu,Jing Zhao

DOI: https://doi.org/10.1007/s00415-024-12536-5

2024-01-01

Journal of Neurology

Abstract:Impaired cardiac function was suggested to be implicated in the functional recovery after ischemic stroke, but the prognostic value of cardiac biomarkers among ischemic stroke patients remains unclear. We aimed to prospectively explore the associations of serum lactate dehydrogenase (LDH), plasma N-terminal pro-brain natriuretic peptide (NT-proBNP), and plasma high-sensitivity cardiac troponin T (hs-cTnT) with adverse clinical outcomes after ischemic stroke in a large-scale cohort study. We measured serum LDH, plasma NT-proBNP, and plasma hs-cTnT levels at baseline among 5056 ischemic stroke patients from the Minhang Stroke Cohort study. All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was composite outcome of death and major disability (modified Rankin Scale [mRS] score ≥ 3) at 3 months after stroke onset, and secondary outcomes included death and ordered 7-level categorical score of the mRS. During 3 months of follow-up, 1584 patients developed the primary outcome. Baseline serum LDH, plasma NT-proBNP, and plasma hs-cTnT were positively associated with the risk of adverse outcomes after ischemic stroke. The multivariable-adjusted odds ratios of primary outcome for the highest versus lowest quartile of LDH, NT-proBNP, and hs-cTnT were 1.37 (95